Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Third party research

CombiGene: New priorities after strategic decision - VH Corp

Lärkberget

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
* Terminating the CG01 programme
* Implementing cost savings to prolong the financial runway
* Our fair value estimate is under review

Recently, CombiGene announced new priorities in its pipeline and a cost saving programme to prolong its financial runway. Peter Ekolind, the CEO, will comment in a live webcast hosted by Västra Hamnen Corporate Finance on Thursday October 31 at 3pm. After evaluating the prospects of the CG01 programme, including generated preclinical data, IP situation, capital requirements and likelihood of success, CombiGene decided to terminate the programme. The company will still be looking for a potential partner for CG01. CombiGene will now focus its R&D investments on the COZY programme for the treatment of chronic pain. Our fair value estimate is under review.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.